DP051 | VENETOCLAX-RITUXIMAB FIXED DURATION TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFTER BTK-INHIBITORS OR CHEMIO-IMMUNOTHERAPY FAILURE: EFFICACY AND SAFETY RESULTS OF A RETROSPECTIVE MULTICENTER STUDY FROM THE REGIONAL CAMPANIA NETWORK

In both first line and relapsed/refractory (R/R) settings, targeted agent-based therapies, such as venetoclax plus Rituximab (R) and covalent Bruton tyrosine kinase inhibitors (BTKis), have outperformed chemoimmunotherapy (CHT-I) in treating pts (pts) with chronic lymphocytic leukaemia (CLL). Never...

Descripció completa

Dades bibliogràfiques

Autors principals:	C. Giordano, G. Farina, M. Lucignano, F. Trastulli, F. Graziani, G.R. Nunziata, V. Amico, R. Reina, V. Sammartano, M. Troiano, L. Mettivier, B. Pocali, M.R. Villa, G. D'arena, S. Basile, A. Fresa, M.G. Ferrara, M. Picardi
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2025-09-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/12681
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!